High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: A pilot study

Journal of Oral Pathology and Medicine

Volumn 41, Issue 2, 2012, Pages 136-140

  Lionello, Marco ^a   Blandamura, Stella ^a   Loreggian, Lucio ^b   Ottaviano, Giancarlo ^a   Giacomelli, Luciano ^a   Marchese Ragona, Rosario ^a   Velardita, Carmelita ^a   Staffieri, Alberto ^a   Marioni, Gino ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Laryngeal carcinoma; Mammalian target of rapamycin; Postoperative radiotherapy; Rapalogs; Targeted therapy

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856438701     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01083.x     Document Type: Article

References (22)

1. Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009; 31: 748-58.
2. Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 2009; 18: 1174-82.
3. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116(Suppl 111): 1-13.
4. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutical target against cancer. Cancer Biol Ther 2003; 2: S169-S177.
5. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009; 35: 148-59.
6. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006; 5: 1065-73.
7. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro and anti-apoptotic. Cell Death Differ 2002; 9: 99-100.
8. Mamane Y, Petroulakis E, Lebacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-22.
9. Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009; 15: 1821-9.
10. No JH, Jeon YT, Park IA, et al. Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit 2009; 15: 301-5.
11. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 2006; 32: 504-15.
12. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th edn. New York, NY: Springer, 2002.
13. Jiang H, Yang BB. p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. Acta Otolaryngol (Stockh) 2009; 129: 101-7.
14. Clark C, Shah S, Herman-Fernandez L, et al. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 2010; 120: 1159-65.
15. Marioni G, Staffieri A, Giacomelli L, et al. Mammalian target of rapamycin (mTOR) expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence. Histopathology 2011; 58: 1148-1156.
16. Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010; 16: 1348-54.
17. Caron E, Ghosh S, Matsuoka Y, et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol 2010; 6: 453.
18. Bozec A, Etienne-Grimaldi MC, Fischel JL, et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011; 47: 340-344.
19. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009; 8: 2255-65.
20. Shinohara ET, Maity A, Jha N, Lustig RA. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head Neck 2009; 31: 406-11.
21. Ekshyyan O, Mills GM, Lian T, et al. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck 2010; 32: 1619-28.
22. Cohen EE, Sharma MR, Janisch L, et al. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer 2011; 47: 1484-9.